MedTrace Logo

Prostaglandin and Cannabinoid Receptors in EoE

NCT04626609 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2025-05-02

No results posted yet for this study

Summary

The purpose of this study is to investigate prostaglandin and cannabinoid receptors and their endogenous ligands in eosinophilic esophagitis (EoE). A prostaglandin D2 receptor antagonist has been shown to improve disease symptoms suggesting a regulatory role for bioactive lipids in EoE. Prostaglandin D2 and E2, and endocannabinoids are lipid mediators that govern the functional and inflammatory behavior of immune cells critical for EoE development. The prostaglandin D2 and E2 receptor axis, and the components of the endocannabinoid may be involved in the pathogenesis of EoE.

Conditions

  • Eosinophilic Esophagitis (EoE)

Interventions

OTHER

Biopsy samples

Esophageal mucosal biopsies are collected during gastroscopy

OTHER

Blood samples

Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Rudolf Schicho, PhD · Medical University of Graz

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-11-01
Completion
2024-11-18

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04626609 on ClinicalTrials.gov